Chimin Health Management's subsidiary, DB006 Oncolytic Adenovirus Injection, has received the drug clinical trial approval notice.

Chimin Health Management (603222.SH) announced that its holding subsidiary, Hainan Jimin Boao International Hospital Co., Ltd. (referred to as "Boao International Hospital"), has received the approval notice for the clinical trial of "DB006 Oncolytic Adenovirus Injection" issued by the National Medical Products Administration, allowing the clinical trial for end stage malignant solid tumors. Boao International Hospital's DB006 Oncolytic Adenovirus Injection is a gene therapy drug used for the treatment of advanced malignant solid tumors. This product has been modified in various aspects using genetic engineering methods to achieve selective infection of tumor cells, enhance the virus's tumor-specific replication ability; meanwhile, the product introduces multiple anti-tumor and immune regulation genes to kill tumors through multiple targets.